logo
Plus   Neg
Share
Email

Company Spotlight: Pulse Biosciences

Pulsebioscience-021717.jpg

Shares of development-stage medical technology company Pulse Biosciences Inc. (PLSE) have gained more than 25% so far this week.

The company's proprietary technology is called Nano-Pulse Stimulation, or NPS, which has a potential to be used in oncology, dermatology, aesthetics as well as other minimally invasive applications.

In pre-clinical testing, NPS has demonstrated its potential to effectively trigger immunogenic cell death, stimulate anti-tumor immunity responses, and inhibit metastases in a variety of oncologic conditions.

Last November, in a pilot study, the company successfully tested its first-of-its-kind PulseTx System, which is based on NPS technology, in dermatology. The pilot study evaluated a range of NPS doses in abdominal skin that will later be resected (cut off) during a standard abdominoplasty ("tummy tuck"). The objective of the study was to establish the response and recovery time of skin to different NPS doses.

The other potential opportunities of dermatologic conditions, which the company has identified for treatment with its PulseTx System, are warts, seborrheic keratosis, actinic keratosis, squamous cell carcinoma, and basal cell carcinoma.

The company had its initial public offering on May 18, 2016 at a price of $4.00 per share.

Key Data

- Revenue - Nil
- Accumulated deficit - $9.79 million
- Cash on hand - $4.63 million
- Shares Outstanding - 13.32 million

(The above data is sourced from the most recent quarterly report filed on November 14, 2016).

Recent event

On February 10, 2017, the company announced that former Pharmacyclics executives, Robert "Bob" Duggan and Maky Zanganeh, have taken a combined stake of 17.1% in Pulse Biosciences - with Duggan owning 15.1% and Zanganeh owning 2.0%.

PLSE has thus far hit a low of $4.03 and a high of $12.90. The stock closed Thursday's trading at $12.25, up 4.26%.

For comments and feedback contact: editorial@rttnews.com

Business News

Follow RTT